Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

Chaurasia B, Tippetts TS,Mayoral Monibas R,Liu J,Li Y,Wang L, Wilkerson JL,Sweeney CR, Pereira RF,Sumida DH,Maschek JA, Cox JE,Kaddai V, Lancaster GI, Siddique MM,Poss A,Pearson M,Satapati S,Zhou H, McLaren DG, Previs SF,Chen Y,Qian Y,Petrov A,Wu M,Shen X,Yao J, Nunes CN, Howard AD, Wang L, Erion MD,Rutter J, Holland WL, Kelley DE,Summers SA

Yearbook of Paediatric Endocrinology（2020）

引用 236|浏览93

暂无评分

摘要

By genetically engineering mice, the authors deleted the enzyme dihydroceramide desaturase 1 (DES1), which normally inserts a conserved double bond into the backbone of ceramides. Ablation of DES1 from whole animals or tissue-specific deletion in the liver and/or adipose tissue resolved hepatic steatosis and insulin resistance in mice caused by leptin deficiency or obesogenic diets

查看译文

关键词

Hepatic Steatosis,Lipid Dysregulation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要